


# SOMAI 2.5:25 INDICA MINT

## SOMAI 2.5:25 INDICA MINT

Different THC/CBD ratios to enable a tailored treatment



RRP  
£84



CBD OIL  
INDICA MINT

30mL

### SOMAI 2.5:25 CBD OIL



CBD

### POTENTIAL THERAPEUTIC INDICATIONS

- Chronic Pain<sup>1</sup>
- Mental Health Conditions<sup>2,3</sup>
- Other Indications as Clinically Justified

For Healthcare Practitioners Only

SOMAI PHARMACEUTICALS LTD  
medical@somaiapharma.co.uk

# SOMAI 2.5:25 INDICA MINT

## SOMAI 2.5:25 INDICA MINT

### Titration and Dosing

THESE TITRATION MODELS SERVE AS AN EXAMPLE AND MUST BE ADAPTED TO EACH PATIENT



Days	Morning dose (mL of oral solution)	Evening dose (mL of oral solution)	Total daily dose (mL of oral solution)	THC total daily dose	
				THC (mg)	CBD (mg)
1-2*	0	1	1	2.5	25
3-4	1	1	2	5	50
5-6	1	2	3	7.5	55
7-8	2	2	4	10	100
9-10	2	3	5	12.5	125


#### Titration scheme and practical dosing recommendations

The patient should take the minimum dose that provides effective symptom relief with tolerable side effects.<sup>4</sup> The titration should be conservative, done with increments of 2.5 mg THC every 2 days (or with increments of 1.25 mg THC for fragile patients).<sup>4</sup>

The dosage protocol can be adjusted according to the patient's profile. Increase dose as necessary and as tolerated, up to 15 mg of THC. Daily THC doses exceeding 20-30 mg may elevate the risk of adverse events or lead to the development of tolerance without improving efficacy.<sup>10</sup> Maximum recommended daily THC dose: 40 mg.<sup>4,5</sup>


\*Ideally, the administration should start with an evening dose to limit adverse events and encourage the development of tolerance.<sup>6</sup>

## MINOR CANNABINOIDS PROFILE\*\*\*



Tests	Minor Cannabinoids Relative Content (%)
CBC	70%
CBG	11%
CBN	6%
CBDV	4%
CBV	2%
Other	6%

## TERPENES PROFILE\*\*



\*Relative content of minor cannabinoids is calculated based on the total of minor cannabinoids.

\*\*These percentages are relative and have been determined using high-performance liquid chromatography as part of our quality control process. Please note that they may vary from batch to batch.

1. Therapeutic Goods Administration (TGA). "Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia". January 25, 2024. <https://www.tga.gov.au/medicinal-cannabis-guidance-documents>. Accessed July 2024. 2. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. *J Clin Med Res.* 2020;12(3):129-141. doi:10.14740/jocmr4090. 3. Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. *NeuroToxicology.* 2019; 74:282-298. doi:10.1016/j.neuro.2019.08.002. 4. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine.* 2018; 49: 12-19. 5. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. *J Clin Med Res.* 2020;12(3):129-141. doi:10.14740/jocmr4090. 6. Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. *J Cannabis Res.* 2021; 3(1): 22.

For Healthcare Practitioners Only